U.S FDA has accepted IND application for COMP360 in PTSD, enabling the initiation of a Phase 2b/3 (COMP202) clinical trial in patients living with PTSD.

Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking ...

(Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today ...

Novel immunotherapy combination regimen brings together two complementary therapies to improve outcomes for people living with multiple myeloma as early as second line1 ...

In summary, a buyer today should look for a partner who can meet design demands, maintain international safety certifications (CE, FDA), support OEM/ODM customisation, handle sports-application lenses ...

As a drone glided across farmland on a December day in Truro, N.S., its robotic voice called out, "enable spraying." Two ...

The Structural Evolution of Global Flavor Systems The international market for seasonings and flavor enhancers is currently ...

FDA accepts BLA for INO-3107, a DNA immunotherapy for HPV-6 and HPV-11-associated recurrent respiratory papillomatosis.

For international distributors seeking a reliable Japanese Style Dried Ramen Noodles factory, the Yumart brand offers a ...

Phase 3 programs underway for DURAVYU in wet AMD and DME, the largest multi-billion-dollar retinal disease markets –– Pivotal Phase 3 trials in ...

Learn how to create burndown charts to track project progress, improve team performance, and download free templates to get ...

Why we love it: Glossier UltraLip glides on like a soft balm but gives the vibrant colour payoff of a lipstick. Its creamy ...